Role of vitamin D in pediatric irritable bowel syndrome
WEN Yi, JIANG Mi-Zu
Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine/National Clinical Research Center for Child Health/National Children′s Regional Medical Center, Hangzhou 310052, China
Abstract：Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease in children and has the clinical manifestations of recurrent abdominal pain with the changes in defecation frequency or stool form. Many studies have shown that children with IBS have a significantly lower vitamin D level than the healthy population, and vitamin D supplementation can significantly improve the clinical symptoms and quality of life of the children, suggesting that vitamin D supplementation may play a role in the treatment of IBS. This article reviews the association between vitamin D and IBS in children and elaborates on the possible mechanism of action of vitamin D.
Devanarayana NM, Rajindrajith S, Pathmeswaran A, et al. Epidemiology of irritable bowel syndrome in children and adolescents in Asia[J]. J Pediatr Gastroenterol Nutr, 2015, 60(6):792-798.
[2]
Koppen IJ, Nurko S, Saps M, et al. The pediatric Rome IV criteria:what's new?[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(3):193-201.
[3]
Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children:current knowledge, challenges and opportunities[J]. World J Gastroenterol, 2018, 24(21):2211-2235.
[4]
Barbalho SM, Goulart RA, Araújo AC, et al. Irritable bowel syndrome:a review of the general aspects and the potential role of vitamin D[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4):345-359.
[5]
Nwosu BU, Maranda L, Candela N. Vitamin D status in pediatric irritable bowel syndrome[J]. PLoS One, 2017, 12(2):e0172183.
[6]
Cho Y, Lee Y, Choi Y, et al. Association of the vitamin D level and quality of school life in adolescents with irritable bowel syndrome[J]. J Clin Med, 2018, 7(12):500.
[7]
Khayyat Y, Attar S. Vitamin D deficiency in patients with irritable bowel syndrome:does it exist?[J]. Oman Med J, 2015, 30(2):115-118.
[8]
El Amrousy D, Hassan S, El Ashry H, et al. Vitamin D supplementation in adolescents with irritable bowel syndrome:is it useful? A randomized controlled trial[J]. Saudi J Gastroenterol, 2018, 24(2):109-114.
[9]
Abbasnezhad A, Amani R, Hajiani E, et al. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients:a randomized double-blind clinical trial[J]. Neurogastroenterol Motil, 2016, 28(10):1533-1544.
[10]
Williams CE, Williams EA, Corfe BM. Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms:what do we know and what do we need to know?[J]. Eur J Clin Nutr, 2018, 72(10):1358-1363.
[11]
Saggese G, Vierucci F, Prodam F, et al. Vitamin D in pediatric age:consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians[J]. Ital J Pediatr, 2018, 44(1):51.
[12]
Dobson R, Cock HR, Brex P, et al. Vitamin D supplemen-tation[J]. Pract Neurol, 2018, 18(1):35-42.
[13]
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine:what clinicians need to know[J]. J Clin Endocrinol Metab, 2011, 96(1):53-58.
[14]
Vogiatzi MG, Jacobson-Dickman E, DeBoer MD, et al. Vitamin D supplementation and risk of toxicity in pediatrics:a review of current literature[J]. J Clin Endocrinol Metab, 2014, 99(4):1132-1141.
[15]
Rizzoli R. Vitamin D supplementation:upper limit for safety revisited?[J]. Aging Clin Exp Res, 2020. DOI:10.1007/s40520-020-01678-x. Epub ahead of print.
[16]
Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D:metabolism, molecular mechanism of action, and pleiotropic effects[J]. Physiol Rev, 2016, 96(1):365-408.
[17]
Gil Á, Plaza-Diaz J, Mesa MD. Vitamin D:classic and novel actions[J]. Ann Nutr Metab, 2018, 72(2):87-95.
[18]
Barbáchano A, Fernández-Barral A, Ferrer-Mayorga G, et al. The endocrine vitamin D system in the gut[J]. Mol Cell Endocrinol, 2017, 453:79-87.
[19]
Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome:mechanisms and practical management[J]. Gut, 2007, 56(12):1770-1798.
[20]
Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome[J]. Gastroenterology, 2007, 132(3):913-920.
[21]
Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability-a new target for disease prevention and therapy[J]. BMC Gastroenterol, 2014, 14:189.
[22]
Du J, Chen YZ, Shi YY, et al. 1,25-Dihydroxyvitamin D protects intestinal epithelial barrier by regulating the myosin light chain kinase signaling pathway[J]. Inflamm Bowel Dis, 2015, 21(11):2495-2506.
[23]
Lagishetty V, Liu NQ, Hewison M. Vitamin D metabolism and innate immunity[J]. Mol Cell Endocrinol, 2011, 347(1/2):97-105.
[24]
He L, Zhou M, Li YC. Vitamin D/vitamin D receptor signaling is required for normal development and function of group 3 innate lymphoid cells in the gut[J]. iScience, 2019, 17:119-131.
[25]
Zhu T, Liu TJ, Shi YY, et al. Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis[J]. Int J Mol Med, 2015, 35(5):1213-1218.
[26]
Proal AD, Albert PJ, Marshall TG. The human microbiome and autoimmunity[J]. Curr Opin Rheumatol, 2013, 25(2):234-240.
[27]
von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells[J]. Nat Immunol, 2010, 11(4):344-349.
[28]
Almerighi C, Sinistro A, Cavazza A, et al. 1Alpha, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes[J]. Cytokine, 2009, 45(3):190-197.
[29]
Baeke F, Takiishi T, Korf H, et al. Vitamin D:modulator of the immune system[J]. Curr Opin Pharmacol, 2010, 10(4):482-496.
[30]
Amani R, Abbasnezhad A, Hajiani E, et al. Vitamin D3 induced decrease in IL-17 and malondialdehyde, and increase in IL-10 and total antioxidant capacity levels in patients with irritable bowel syndrome[J]. Iran J Immunol, 2018, 15(3):186-196.
[31]
Zhang L, Song J, Hou XH. Mast cells and irritable bowel syndrome:from the bench to the bedside[J]. J Neurogas-troenterol Motil, 2016, 22(2):181-192.
[32]
Liu ZQ, Li XX, Qiu SQ, et al. Vitamin D contributes to mast cell stabilization[J]. Allergy, 2017, 72(8):1184-1192.
[33]
Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3[J]. J Immunol, 2009, 183(9):5458-5467.
[34]
Harrison SR, Li DY, Jeffery LE, et al. Vitamin D, autoimmune disease and rheumatoid arthritis[J]. Calcif Tissue Int, 2020, 106(1):58-75.
[35]
Shang M, Sun J. Vitamin D/VDR, probiotics, and gastrointes-tinal diseases[J]. Curr Med Chem, 2017, 24(9):876-887.
[36]
Battault S, Whiting SJ, Peltier SL, et al. Vitamin D metabolism, functions and needs:from science to health claims[J]. Eur J Nutr, 2013, 52(2):429-441.
[37]
Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease[J]. Ann N Y Acad Sci, 2009, 1173:757-765.
[38]
Mukherji A, Kobiita A, Ye T, et al. Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs[J]. Cell, 2013, 153(4):812-827.
[39]
Kim JH, Yamaori S, Tanabe T, et al. Implication of intestinal VDR deficiency in inflammatory bowel disease[J]. Biochim Biophys Acta, 2013, 1830(1):2118-2128.
[40]
Jin DP, Wu SP, Zhang YG, et al. Lack of vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome[J]. Clin Ther, 2015, 37(5):996-1009.e7.
[41]
Bashir M, Prietl B, Tauschmann M, et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract[J]. Eur J Nutr, 2016, 55(4):1479-1489.
[42]
Naderpoor N, Mousa A, Fernanda Gomez Arango L, et al. Effect of vitamin D supplementation on faecal microbiota:a randomised clinical trial[J]. Nutrients, 2019, 11(12):2888.
[43]
Singh V, Roth S, Llovera G, et al. Microbiota dysbiosis controls the neuroinflflammatory response after stroke[J]. J Neurosci, 2016, 36(28):7428-7440.
[44]
Martin CR, Osadchiy V, Kalani A, et al. The brain-gut-microbiome axis[J]. Cell Mol Gastroenterol Hepatol, 2018, 6(2):133-148.
[45]
Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis[J]. Cell, 2015, 161(2):264-276.
[46]
Bohórquez DV, Liddle RA. The gut connectome:making sense of what you eat[J]. J Clin Invest, 2015, 125(3):888-890.
